Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAS2R14 | Q9NYV8 | 1/20 | 0.34 |
| ▸ | TP53 | P04637 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.33 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.33 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.33 |
| ▸ | CXCR3 | P49682 | 1/20 | 0.33 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.32 |
| ▸ | GLA | P06280 | 1/20 | 0.32 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.32 |
| ▸ | S100A9 | P06702 | 1/20 | 0.32 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19970508 | 1.00 | TAS2R14 (0.34) | TAS2R14TP53KMT2ARXFP1HSD11B1 | |
| SCHEMBL19970524 | 1.00 | TAS2R14 (0.34) | TAS2R14TP53KMT2ARXFP1HSD11B1 | |
| SCHEMBL19970478 | 0.88 | ALDH1A1 (0.40) | TAS2R14TP53KMT2AAKR1C3 | |
| SCHEMBL19970504 | 0.88 | ALDH1A1 (0.40) | TAS2R14TP53KMT2AAKR1C3 | |
| SCHEMBL20111171 | 0.87 | KMT2A (0.37) | TP53KMT2A | |
| SCHEMBL20111184 | 0.87 | KMT2A (0.37) | TP53KMT2A | |
| SCHEMBL19970476 | 0.87 | GRM2 (0.38) | KMT2A | |
| SCHEMBL19970533 | 0.82 | LMNA (0.36) | KMT2A | |
| SCHEMBL19970525 | 0.82 | LMNA (0.36) | KMT2A | |
| SCHEMBL19970507 | 0.81 | P2RX7 (0.31) | EPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180118708-A1 | CYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2018-05-03 | — | — | US | disclosed |
| EP-3296296-A1 | CYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2018-03-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180118708-A1 | CYCLIC COMPOUND | TLR4, TLR3, TLR9 | TAS2R14 2447/4885TP53 562/4885KMT2A 3879/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.